

AI Maverick Intel, Inc.

formerly Bionoid Pharma, Inc.

5480 Glen Erin Drive
Unit 105
Mississauga, Ontario
L5M 5R3 CANADA

(905) 505-0770

<https://aimaverickintel.com/>

wayne@bionoidinc.com

SIC Code: 5099

Quarterly Report

For the period ending June 30, 2025 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

53,994,610 as of June 30, 2025

53,994,610 as of December 31, 2024

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Impact Medical Solutions, Inc. June 27, 2006 – May 22, 2009
iTech Medical, Inc. May 22, 2009 – January 8, 2020
Kavtek Software, Corp. January 8, 2020 – July 22, 2020
Bionoid Pharma, Inc. July 22, 2020 – February 22, 2022
Bionoid, Inc. February 22, 2022 – August 11, 2022
BIN Holdings, Inc. August 11, 2022 – June 13, 2023
Bionoid Pharma, Inc. June 13, 2023 – March 15, 2025
AI Maverick Intel, Inc. March 15, 2025 - present

Current State and Date of Incorporation or Registration: Delaware June 27,2006

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

The company acquired the intellectual property of AI Maverick Intel from Stronghold Media Group Corp. in August 2024 and divested its 100% ownership of Medical Magnetics Inc.

Address of the issuer's principal executive office:

5480 Glen Erin Drive
Unit 105
Mississauga, Ontario
L5M 5R3 CANADA

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Securities Transfer Corp.
Phone: 469-633-0101, ext. 106
Email: johnson@stctransfer.com
Address: 2591 Dallas Parkway, Suite 102, Frisco, Texas 75034

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>BINP</u>	
Exact title and class of securities outstanding:	<u>Class A Common Shares</u>	
CUSIP:	<u>09076D101</u>	
Par or stated value:	<u>0.0001</u>	
Total shares authorized:	<u>260,000,000</u>	as of date: <u>June 30, 2025</u>
Total shares outstanding:	<u>53,994,610</u>	as of date: <u>June 30, 2025</u>
Total number of shareholders of record:	<u>120</u>	as of date: <u>June 30, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred</u>	
CUSIP (if applicable):	<u>n/a</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>June 30, 2025</u>
Total shares outstanding (if applicable):	<u>10,000,000</u>	as of date: <u>June 30, 2025</u>
Total number of shareholders of record:	<u>2</u>	as of date: <u>June 30, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.**

Voting Rights

Stockholders are entitled to one vote on all matters to be voted upon for each share of common stock held. The shares do not have the right to cumulative voting for directors, meaning that holders of more than 50 percent of the shares voting for the election of directors can elect all of the directors if they choose to do so.

Liquidation Rights

In the event of liquidation, dissolution or a winding up the company's affairs, holders of common stock would be entitled to receive pro rata all of the company's remaining assets that are available and distributable to the shareholders after first satisfying the claims of creditors and anyone else having rights that are superior to those of the common stockholders.

Pre-emptive Rights

Stockholders do not have a pre-emptive right to acquire the company's unissued shares of common stock.

Dividends and Dividend Policy

To date, the company has neither declared nor paid any dividends on its common stock, nor does it anticipate that such dividends will be paid in the foreseeable future.

-
2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Each Preferred Share is convertible into 10 shares of Common Stock at the request of the shareholder. There are no redemption rights or sinking fund provisions.

-
3. **Describe any other material rights of common or preferred stockholders.**

None

4. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

None

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u> Date <u>01/01/2023</u> Common: <u>53,994,610</u> Preferred: <u>10,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
Shares Outstanding on Date of This Report: <u>Ending Balance:</u> Date <u>06/30/2025</u> Common: <u>53,994,610</u> Preferred: <u>10,000,000</u>									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

None.

B. Convertible Debt

The following is a complete list of the Company’s Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer’s equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁵	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below:

None.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

As of June 30, 2025, AI Maverick Intel, Inc. is a technology-focused company developing proprietary software solutions that leverage artificial intelligence (AI) and automation to optimize customer acquisition and audience engagement. Current operations are centered on developing, marketing, and licensing its AI Maverick Intel platform, acquired in August 2024, with plans to scale into commercial AI deployment.

- B. List any subsidiaries, parent company, or affiliated companies.

As of June 30, 2025, AI Maverick Intel, Inc. has no active subsidiaries. There is no parent company or affiliated company.

- C. Describe the issuers' principal products or services.

The Company's principal asset is its proprietary AI Maverick Intel platform, which is designed to automate and enhance customer acquisition processes using machine learning, behavioral data analysis, and performance-driven optimization. The platform is intended to support digital marketing, sales automation, and growth strategies for businesses seeking to scale efficiently. AI Maverick expects to generate future revenue through SaaS licensing, enterprise integration, and consulting services based on its AI technology stack.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company occupies virtual space in Mississauga, Ontario, Canada. Its programmers work from home in Ecuador and Canada.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
<u>Wayne Cockburn</u>	<u>Officer, Director</u>	<u>Toronto, Ontario</u>	<u>3,945,622</u>	<u>Common</u>	<u>7.1%</u>
<u>Flora C LLC, Ariel Maman</u>	<u>>5%</u>	<u>Denver, CO</u>	<u>37,544,273</u>	<u>Common</u>	<u>67.7%</u>
<u>Dennis Reich</u>	<u>Officer, Director</u>	<u>Sudbury, Ontario</u>	<u>500,000</u>	<u>Common</u>	<u>0.9%</u>
<u>Chelsea Stepp</u>	<u>Director</u>	<u>Whitby, Ontario</u>	-	-	-
<u>Wayne Cockburn</u>	<u>Officer, Director</u>	<u>Toronto, Ontario</u>	<u>7,650,000</u>	<u>Preferred</u>	<u>76%</u>
<u>Tim McKinnon</u>	<u>>5%</u>	<u>Mississauga, Ontario</u>	<u>2,350,000</u>	<u>Preferred</u>	<u>24%</u>

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined,

barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) **Third Party Service Providers**

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:	<u>Andy Farber</u>
Address 1:	<u>20283 State Road 7</u>
Address 2:	<u>Boca Raton, FL 33498</u>
Phone:	<u>954-304-3983</u>
Email:	<u>aefarber@gmail.com</u>

Accountant or Auditor

Name: Paul Riss
Firm: ICF Industries Inc
Address 1: 800 Westchester Ave Suite 641N
Address 2: Rye Brook, NY 10573
Phone: 914-415-4454
Email: paulriss77@gmail.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): @AIMaverickIntel
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Wayne Cockburn
Title: CEO
Relationship to Issuer: Officer, Director

B. The following financial statements were prepared in accordance with:

- IFRS
- U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Paul Riss
Title: Accountant
Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Mr. Riss is a CPA

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

**AI MAVERICK INTEL INC.
(F/K/A BIONOID PHARMA, INC.)**

UNAUDITED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024

AI Maverick Intel Inc.
(f/k/a Bionoid Pharma, Inc.)
Consolidated Balance Sheets
Unaudited

	<u>June 30, 2025</u>	<u>December 31, 2024</u>
ASSETS		
Current assets:		
Cash	\$ -	\$ -
Total current assets	-	-
Intangible assets	4,077,715	4,423,429
Total assets	\$ 4,077,715	\$ 4,423,429
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 80,613	\$ 250
Wages payable - officer	30,000	-
Loan payable - related party	16,429	16,429
Accrued interest payable - related party	23,265	22,450
Total current liabilities	150,307	39,129
Total liabilities	150,307	39,129
Commitments and contingencies	-	-
Preferred Stock, par value \$0.001, 10,000,000 shares authorized, 10,000,000 shares issued and outstanding in 2023 and 2022	10,000	10,000
Common stock, par value \$0.0001; 250,000,000 shares authorized, 53,994,610 issued and outstanding in 2025 and 2024	5,399	5,399
Paid-in-capital	23,863,419	23,863,419
Accumulated deficit	(19,951,410)	(19,494,518)
Total shareholders' equity	3,927,408	4,384,300
Total liabilities and shareholders' equity	\$ 4,077,715	\$ 4,423,429

See accompanying notes to the consolidated financial statements.

AI Maverick Intel Inc.
(f/k/a Bionoid Pharma, Inc.)
Consolidated Statements of Operations
Unaudited

	Three Months Ended June 30, 2025	Three Months Ended June 30, 2024	Six Months Ended June 30, 2025	Six Months Ended June 30, 2024
Revenue	\$ -	\$ 5,142	\$ -	\$ 9,958
Cost of sales		2,472	-	4,604
Gross profit	-	2,670	-	5,354
Expenses:				
Salary expense	15,000	-	30,000	-
Office and administration	22,113	1,949	80,363	4,280
Total expenses	37,113	1,949	110,363	4,280
Income from operations	(37,113)	721	(110,363)	1,074
Other income (expenses):				
Interest expense	(409)	(3,544)	(815)	(3,544)
Amortization	(172,857)	(750)	(345,714)	(1,500)
Total other income (expenses):	(173,266)	(4,294)	(346,529)	(5,044)
Net income (loss) from continuing operations before tax	(210,379)	(3,573)	(456,892)	(3,970)
Income tax expense	-	-	-	-
Income (loss) from continuing operations	(210,379)	(3,573)	(456,892)	(3,970)
Discontinued operations:				
Gain from discontinued operations, net of tax	-	-	-	-
Loss on disposal of discontinued operations	-	-	-	-
Net income (loss) from discontinued operations	-	-	-	-
Net income (loss)	\$ (210,379)	\$ (3,573)	\$ (456,892)	\$ (3,970)
Basic net income per share	\$ (0.00)	\$ (0.00)	\$ (0.01)	\$ (0.00)
Diluted income per share	\$ (0.00)	\$ (0.00)	\$ (0.01)	\$ (0.00)
Weighted average number of shares outstanding				
Basic	53,994,610	53,994,610	53,994,610	53,994,610
Diluted	53,994,610	53,994,610	53,994,610	53,994,610

See accompanying notes to the consolidated financial statements.

AI Maverick Intel Inc.
(f/k/a Bionoid Pharma, Inc.)
Consolidated Statements of Changes in Shareholders' Equity
For the Six Months Ended June 30, 2025 and the Years Ended December 31, 2024 and 2023
Unaudited

	Common Stock		Preferred Stock		Paid-in-Capital	Accumulated Deficit	Shareholders' Equity
	Shares	Amount	Shares	Amount			
Balance, December 31, 2022	53,994,610	\$ 5,399	10,000,000	\$ 10,000	\$ 19,163,419	\$ (19,189,555)	\$ (10,737)
Net income year ended December 31, 2023	-	-	-	-	-	11,725	11,725
Balance, December 31, 2023	53,994,610	5,399	10,000,000	10,000	19,163,419	(19,177,830)	988
Cancellation of preferred stock	-	-	(2,350,000)	(2,350)	2,350	-	-
Purchase of AI Marvericks	-	-	2,350,000	2,350	4,697,650	-	4,700,000
Net loss year ended December 31, 2024	-	-	-	-	-	(316,688)	(316,688)
Balance, December 31, 2024	53,994,610	5,399	10,000,000	10,000	23,863,419	(19,494,518)	4,384,300
Net loss quarter ended March 31, 2025	-	-	-	-	-	(246,513)	(246,513)
Balance, March 31, 2025	53,994,610	5,399	10,000,000	10,000	23,863,419	(19,741,031)	4,137,787
Net loss quarter ended June 30, 2025	-	-	-	-	-	(210,379)	(210,379)
Balance, June 30, 2025	53,994,610	\$ 5,399	10,000,000	\$ 10,000	\$ 23,863,419	\$ (19,951,410)	\$ 3,927,408

See accompanying notes to the consolidated financial statements.

AI Maverick Intel Inc.
(f/k/a Bionoid Pharma, Inc.)
Consolidated Statements of Cash Flows
Unaudited

	Six Months Ended June 30, 2025	Six Months Ended June 30, 2024
Cash flows from operating activities:		
Net loss	\$ (456,892)	\$ (3,970)
Adjustment to reconcile net income to net cash provided by operating activities:		
Amortization	345,714	1,500
Changes in working capital items:		
Other current assets	-	(885)
Wages payable - officer	30,000	-
Accrued interest payable - related party	815	-
Accounts payable and accrued liabilities	80,363	3,436
Net cash provided by operating activities	-	81
Net cash increase for period	-	81
Cash at beginning of period	-	2,686
Cash at end of period	\$ -	\$ 2,767
Supplemental disclosure of cash flow information:		
Cash paid during the period for:		
Income taxes	\$ -	\$ -
Interest	\$ -	\$ -

See accompanying notes to the consolidated financial statements.

AI Maverick Intel, Inc.
(f/k/a Bionoid Pharma, Inc.)
Notes to the Consolidated Financial Statements
June 30, 2025
Unaudited

Note 1 – Organization of Business

AI Maverick Intel, Inc. (the "Company") was incorporated on September 27, 2006, under the laws of the State of Delaware. The Company currently operates as a technology-driven business focused on leveraging artificial intelligence (AI) and automation to redefine customer acquisition and audience engagement processes.

In 2024, the Company completed the acquisition of the intellectual property of AI Maverick Intel from Stronghold Media Group Corp. AI Maverick Intel is an advanced platform that automates customer acquisition and scaling, representing a significant expansion of the Company's AI capabilities. The acquisition aligns with the Company's strategic initiatives to focus on innovative, AI-driven solutions.

In conjunction with this acquisition, the Company divested its 100% ownership of Medical Magnetics Inc. (formerly BIOflex Medical Magnetics Inc.) to streamline its operations and concentrate on AI and automation. The sale of Medical Magnetics Inc. was completed for nominal consideration as part of the Company's realignment strategy.

Basis of Presentation

The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company has a December 31 year end.

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income tax valuation allowance and the amortization life of intangible assets. On a continual basis, management reviews its estimates, utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company has no cash equivalents. The Company has not maintained cash balances that exceed federally insured limits.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which established principles for recognizing revenue using a five-step model. The Company applies this model as follows:

1. Identification of the Contract: The Company identifies contracts with customers as legally enforceable agreements that specify the terms of the transaction, rights, and obligations of each party.
2. Identification of Performance Obligations: For each contract, the Company determines whether the agreement contains distinct performance obligations that must be separately satisfied.
3. Determination of the Transaction Price: The Company considers the consideration expected to be entitled from the customer in exchange for transferring goods or services. Given the Company's nominal revenue, there are no significant judgments related to variable consideration or discounts.
4. Allocation of the Transaction Price: The Company allocates the transaction price to each performance obligation based on its relative standalone selling price if there are multiple obligations within a contract.
5. Recognition of Revenue: Revenue is recognized when or as the Company satisfies a performance obligation by transferring control of goods or services to the customer. Given the Company's straightforward transactions and nominal revenue, revenue is generally recognized at a single point in time upon completion of the service or delivery of goods.

Fair Value of Financial Instruments

Under the Fair Value Measurements Topic of the FASB Accounting Standards Codification, the Company bases its fair value on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is the Company's policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and, therefore, are based primarily upon management's own estimates, are often calculated based on current pricing policy, the economic and competitive environment, the characteristics of the asset or liability and other such factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, that could significantly affect the results of current or future values.

Impairment of long-lived assets

The Company periodically reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset's estimated fair value and its book value. During the three- and six-month periods ended June 30, 2025 and 2024, the Company did not record any impairment losses.

Stock-Based Compensation

The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation – Stock Compensation which requires all share-based payments to employees, including the vesting of restricted stock grants to employees, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to common stock and capital in excess of par value during the period during which services are rendered.

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for common stock issued to consultants and other non-employees. These shares of common stock are issued as compensation for services provided to the Company and are accounted for based upon the fair market value of the common stock. The fair value of the equity instrument is charged directly to compensation expense, or to prepaid expenses in instances where stock was issued under a contractual arrangement to a consultant who agreed to provide services over a period of time.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. A valuation allowance has been established to eliminate the Company’s deferred tax assets as it is more likely than not that any of the deferred tax assets will be realized.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process whereby (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Based on the Company's history of losses, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company's financial statements. The Company believes that its income tax positions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.

The Company may in the future become subject to foreign, federal, state, and local income taxation though it has not been since inception. The Company is not presently subject to any income tax audit in any taxing jurisdiction.

Basic Income Per Share

Basic income per share is calculated by dividing the Company’s net income applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per

share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the fiscal period. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. As of June 30, 2025 and 2024, the Company had dilutive equity securities outstanding, see Note 7.

Recent Accounting Pronouncements

The Financial Accounting Standards Board (FASB) has issued the following recent accounting pronouncements:

ASU 2024-03 – Expense Disaggregation Disclosures: This update requires companies to provide more detailed breakdowns of certain expenses in financial statement notes, effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027.

The Company has evaluated these pronouncements and does not expect them to have a material impact on its financial position, results of operations, or cash flows. However, they may affect disclosures in future financial reports, as required by the applicable effective dates.

Note 3 – Going Concern Matters and Realization of Assets

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. However, the Company has limited working capital, an accumulated deficit, and incurred operating losses in recent years. The Company believes that its existing cash resources may not be sufficient to fund its working capital requirements.

The Company may not be able to raise sufficient additional debt, equity, or other cash on acceptable terms, if at all. Failure to generate sufficient revenues, raise sufficient funds, or achieve certain other business objectives could have a material adverse effect on the Company's results of operations, cash flows and financial position, including its ability to continue as a going concern, and may require it to significantly reduce, reorganize, discontinue, or shut down its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Accordingly, the Company's management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these financial statements. There can be no assurance that the Company will be able to achieve its business plan objectives or be able to achieve or maintain cash-flow-positive operating results. If the Company is unable to generate adequate funds from operations or raise sufficient additional funds, the Company may not be able to continue to operate its business network, respond to competitive pressures or fund its operations.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in its existence.

Management's plans include the pursuit of financing from known lenders, family members and business friends.

Note 4 – Income Taxes

The Company did not have any material unrecognized tax benefits as of June 30, 2025 and December 31, 2024. The Company does not expect the unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Company recorded no interest and penalties relating to unrecognized tax benefits as of and during the three- and six-month periods ended June 30, 2025, and 2024. The Company is subject to United States federal income tax, as well as taxes by various state jurisdictions.

The Company recorded no income tax expense for the three- and six-month periods ended June 30, 2025, and 2024 due to a tax loss carryforward that is available to offset any taxable income.

Note 5 – Stockholders' Equity

The Company is authorized to issue 250,000,000 shares of common stock, par value \$0.0001 per share and 10,000,000 shares of preferred stock, par value \$0.001. As of June 30, 2025 and December 31, 2024, there were 53,994,610 shares of common stock issued and outstanding and 10,000,000 shares preferred stock issued and outstanding.

Holders of common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders. The shares do not have cumulative voting rights for the election of directors. As a result, holders of a majority of the shares voting for the election of directors can elect all of the directors.

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of common stock are entitled to share ratably in all remaining assets of the Company available for distribution to stockholders after the payment of all liabilities and after satisfaction of any liquidation preferences of any outstanding preferred stock or other securities with liquidation rights senior to the common stock.

Each share of preferred stock is convertible into 10 shares of common stock at the option of the holder. In 2024, a stockholder surrendered 2,350,000 shares of preferred stock, which the Company used as consideration to acquire intellectual property from Stronghold Media Group Corp. related to AI Maverick Intel. The transaction was valued at \$4,700,000.

Note 6 – Fair Value

The Company uses fair value measurements to record adjustments to the carrying values of certain financial and non-financial assets and liabilities and to provide fair value disclosures for financial instruments measured on a recurring basis.

Cash and cash equivalents, other current assets, accrued expenses and loan payable

In general, carrying amounts approximate fair value because of the short maturity of these instruments.

The Fair Value Measurements Topic of the FASB Accounting Standards Codification establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

- Level 1: inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the company has the ability to access at the measurement date.
- Level 2: inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3: inputs are unobservable inputs for the asset or liability.

Under the Fair Value Measurements Topic of the FASB Accounting Standards Codification, the Company bases fair value on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is our policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and, therefore, are based primarily upon management's own estimates, are often calculated based on current pricing policy, the economic and competitive environment, the characteristics of the asset or liability and other such factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows that could significantly affect the results of current or future value.

Note 7 – Earnings (Loss) Per Common Share

Earnings (loss) per common share data for the three- and six-month periods ended June 30, 2025 and 2024 was computed as follows:

	Three Months Ended June 30, 2025	Three Months Ended June 30, 2024	Six Months Ended June 30, 2025	Six Months Ended June 30, 2024
Net income attributable to common stockholders - basic	\$ (210,379)	\$ (3,573)	\$ (456,892)	\$ (3,970)
Adjustments to net income	-	-	-	-
Net income attributable to common stockholders - diluted	\$ (210,379)	\$ (3,573)	\$ (456,892)	\$ (3,970)
Weighted average common shares outstanding - basic	53,994,610	53,994,610	53,994,610	53,994,610
Effect of dilutive securities	-	-	-	-
Weighted average common shares outstanding - diluted	53,994,610	53,994,610	53,994,610	53,994,610
Earnings per share - basic	\$ (0.00)	\$ (0.00)	\$ (0.01)	\$ (0.00)
Earnings per share - diluted	\$ (0.00)	\$ (0.00)	\$ (0.01)	\$ (0.00)

In the three- and six-month periods ended June 30, 2025 and 2024, convertible preferred stock convertible into 100,000,000 shares of common stock was not included in the diluted earnings per share calculation because it was anti-dilutive.

Note 8 – Related Party Transactions

As of June 30, 2025 and December 31, 2024, the Company owes \$16,429 to its Chief Executive Officer for two loans, that have a maturity date of October 31, 2018. Accrued interest of \$23,265 and \$22,450, is payable as of June 30, 2025 and December 31, 2024. The loan is in default.

Note 9 – Loans payable

As of June 30, 2025 and December 31, 2024, the Company owed its Chief Executive Officer \$16,429. The loan was due on October 30, 2018 and is in default. Interest accrues at a rate of 10% annually. Accrued interest payable on the loan amounted to \$23,265 and \$22,450 as of June 30, 2025 and December 31, 2024, respectively.

Note 10 – Intangible Assets and Asset Acquisition

Intangible assets with defined useful lives are generally measured at cost less straight-line amortization. The useful life is determined using the period of the underlying contract or the period of time over which the intangible asset can be expected to be used. Impairments are recognized if the recoverable amount of the asset is lower than the carrying amount. The recoverable amount is the higher of either the fair value less costs to sell or the value in use. The value in use is determined on the basis of future cash inflows and outflows, and the weighted average cost of capital. Intangible assets with indefinite useful lives, such as trade names and trademarks, that have been acquired as part of acquisitions are measured at cost and tested for impairment annually, or if there is an indication that their value has declined.

On August 7, 2024, the Company acquired certain intangible assets, including the AI Maverick Platform, Coding and Programming IP, and a domain, through the issuance of 2,350,000 shares of preferred stock, each convertible into 10 shares of common stock. The preferred stock was valued based on the fair market value of the common shares on the acquisition date, resulting in a total purchase price of \$4,700,000. The purchase price was allocated as follows:

- AI Maverick Platform: \$2,600,000
- Coding and Programming IP: \$1,200,000
- Domain: \$200,000
- Goodwill: \$700,000

The allocation was determined based on the estimated fair values of the acquired assets. The assets have been recorded as intangible assets on our balance sheet, with goodwill recognized for the excess purchase price over the fair values of identifiable assets.

The intangible assets acquired are being amortized over their estimated useful lives, as follows:

- AI Maverick Platform: 5 years
- Coding and Programming IP: 7 years
- Domain: Indefinite life, not amortized
- Goodwill: Indefinite life, not amortized

For book purposes, goodwill and the domain are not amortized but will be tested annually for impairment, or more frequently if indicators of impairment arise.

Amortization of intangible assets is recognized on a straight-line basis over their respective useful lives. Due to the timing of the acquisition, the amortization expense for the year ended December 31, 2024, was recorded for the initial period from August 7, 2024 to December 31 2024 as follows:

- AI Maverick Platform: \$208,000
- Coding and Programming IP: \$68,571

Total amortization expense for the three- and six-month periods ended June 30, 2025 was \$172,857 and \$345,714. Future amortization expense is expected to be approximately \$172,857 per quarter, based on the allocated useful lives. The remaining useful life is approximately 14 years.

Note 10 – Subsequent Events

The Company evaluated all events and transactions that occurred after the balance sheet date through the date the financial statements were available to be issued. Based on this evaluation, the Company determined that there were no subsequent events that required disclosure in the financial statements.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Wayne Cockburn certify that:

1. I have reviewed this Disclosure Statement for AI Maverick Intel, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2025

//Wayne Cockburn// [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Wayne Cockburn certify that:

1. I have reviewed this Disclosure Statement for AI Maverick Intel, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2025

//Wayne Cockburn// [CFO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)